Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci128 in solid tumors with TP53 Y220C mutation
NCT06908434Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GenSci128 in solid tumor (6 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events at 3 weeks, Maximum Tolerated Dose at 3 months and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
GenSci128
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06908434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908434.